- Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURAGrohe, C.; Herbst, R. S.; Tsuboi, M.; John, T.; Majem, M.; Goldman, J. W.; Kim, S. -W.; Marmol, D.; Rukazenkov, Y.; Wu, Y. -L.; Engel-Riedel, W.
- Osimertinib as adjuvant therapy in patients (pts) with stage IBIIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURATsuboi, Masahiro; John, Thomas; Grohe, Christian; Majem, Margarita; Goldman, Jonathan Wade; Kim, Sang-We; Marmol, Dominika; Rukazenkov, Yuri; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2020-05-29 To 2020-05-31.被引 52
- Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).Herbst, Roy S.; Tsuboi, Masahiro; John, Tom; Kato, Terufumi; Majem, Margarita; Grohe, Christian; Wang, Jie; Goldman, Jonathan W.; Lu, Shun; Su, Wu-Chou; De Marinis, Filippo; Shepherd, Frances A.; Lee, Ki Hyeong; Le, Nhieu; Dechaphunkul, Arunee; Kowalski, Dariusz M.; Poole, Lynne; Stachowiak, Marta; Rukazenkov, Yuri; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 12
会议论文
Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results
7被引2阅读
